Condition
DIPG Brain Tumor
Total Trials
6
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 1 (4)
Trial Status
Recruiting3
Not Yet Recruiting1
Terminated1
Unknown1
Clinical Trials (6)
Showing 6 of 6 trials
NCT06465199Phase 1Recruiting
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
NCT05956821Phase 1Recruiting
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
NCT06221553Phase 1RecruitingPrimary
Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG
NCT05500508Phase 1Terminated
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT06439849UnknownPrimary
Single Patient Compassionate Use / Expanded Access L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment of Diffuse Midline Glioma
NCT06396481Early Phase 1Not Yet Recruiting
Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
Showing all 6 trials